Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | BRD4 | O60885 | 4/20 | 0.75 |
| ▸ | BRD2 | P25440 | 2/20 | 0.75 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.75 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.75 |
| ▸ | PDE4A | P27815 | 6/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713301 | 0.96 | MEN1 (0.71) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL9055277 | 0.87 | PDE4A (0.61) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL7457891 | 0.87 | MEN1 (1.00) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL19066317 | 0.86 | BRD4 (1.00) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL7519416 | 0.86 | PDE4A (0.56) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL11399596 | 0.85 | MEN1 (0.95) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL11458744 | 0.84 | MEN1 (0.74) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL9010501 | 0.82 | ADORA2B (0.62) | MEN1KMT2AALDH1A1BRD4BRD2 | |
| SCHEMBL3179304 | 0.81 | PDE4A (0.73) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7031729 | 0.81 | MEN1 (0.87) | MEN1KMT2AALDH1A1BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | disclosed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | disclosed |
| WO-2016119570-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | 上海珊顿医药科技有限公司 | 2016-08-04 | — | — | WO | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| US-20100160354-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-06-24 | — | — | US | disclosed |
| US-7713982-B2 | Xanthines with HM74A receptor activity | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713982-B2 | Xanthines with HM74A receptor activity | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713982-B2 | Xanthines with HM74A receptor activity | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | MEN1 1560/4885KMT2A 2484/4885ALDH1A1 1397/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | MEN1 3009/4885KMT2A 3023/4885ALDH1A1 305/4885 |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | NLRP3, REN, SLC5A1 | MEN1 2275/4885KMT2A 3290/4885ALDH1A1 627/4885 |
| US-20130150383-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | MEN1 3009/4885KMT2A 3023/4885ALDH1A1 305/4885 |
| US-20100160354-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | MEN1 3009/4885KMT2A 3023/4885ALDH1A1 305/4885 |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | REN, NLRP3, SLC5A1 | MEN1 2223/4885KMT2A 3253/4885ALDH1A1 657/4885 |
| US-20100010021-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | MEN1 3009/4885KMT2A 3023/4885ALDH1A1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.